Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Oct;27(3):272–277. doi: 10.1007/BF00205451

Mitogenic, immunoadjuvancy, and genetic studies on fatty acyl maltose

Elyse Bissonnette 1, Ouhida Benrezzak 2, Prometeo Madarnas 2, Carlos Brailovsky 1,2, Vijai N Nigam 1
PMCID: PMC11038134  PMID: 3052844

Abstract

Three synthetic glycolipids, maltose tetrapalmitate (MTP), maltose hexastearate (MHS), and maltose hexalinoleate (MHL) prepared as nontoxic lipid A analogs, and Escherichia coli lipopolysaccharide (LPS) were assayed for their mitogenic activity using spleen lymphocytes in nine inbred mouse strains and three F1 hybrids. The MTP and LPS were also assayed for their ability to enhance plaque-forming cell (PFC) responses using sheep red blood cells as the antigen in th same inbred mouse strains and F1 hybrids, The mitogenic activity of synthetic glycolipids was several fold lower than that of LPS and MHL was inferior to MTP and MHS. DBA/2J was the most responsive strain for MTP and DBA/1J and C3H/HeJ the least. The mitogenic activity of MTP was generally in agreement with the PFC response stimulation by it. Lowdose cyclophosphamide treatment of mice synergized MTP for PFC response augmentation. Genetic studies on MTP mitogenicity revealed that 90% of responder DBA/2J X nonresponder C3H/HeJ F1 hybrids had intermediate mitogenic activity. Among F2, 73% had intermediate-high activity and 27% were nonmitogenic. Among F1 X C3H/HeJ backcrosses 11% had high, 56% intermediate, and 33% had no mitogenic activity, whereas, for the F1 X DBA/2J backcross, 14% had high, 36% intermediate, and 50% low or negligible activity. The data favored a single gene for MTP activation of immune cells.

Keywords: Escherichia Coli, Cyclophosphamide, Genetic Study, Maltose, Fatty Acyl

Footnotes

This work was supported, in part, by a grant from the National Cancer Institute of Canada, and by grant from the Cancer Research Society Inc.

References

  • 1.Behling UH, Campbell B, Chang CM, Rumpf C, Nowotny A. Synthetic glycolipid adjuvants. J Immunol. 1979;117:847. [PubMed] [Google Scholar]
  • 2.Benedetto DA, Shands JW, Jr, Shah DO. The interaction of bacterial lipopolysaccharide with phospholipid bilayers and monolayers. Biochim Biophys Acta. 1973;298:145. doi: 10.1016/0005-2736(73)90346-5. [DOI] [PubMed] [Google Scholar]
  • 3.Benrezzak O, Nigam VN, Madarnas P, Pageau R. Induction of colorectal and epidermoid anal cancer by dimethylhydrazine in CD1 mice and the evaluation of single and combined therapy regimens. Proc Am Assoc Can Res. 1986;27:738. [Google Scholar]
  • 4.Benrezzak O, Nigam VN, Madarnas P, Pageau R. Combined modality treatment of primary lung cancer in A/J mice with maltose tetrapalmitate, radiotherapy and cyclophosphamide. Proc Am Assoc Can Res. 1987;28:450. [Google Scholar]
  • 5.Bonaventure J, Nigam VN, Brailovsky CA. In vitro spleen cell proliferation following in vivo treatment with a synthetic glycolipid or lipid A in three mouse strains. Int J Immunopharmacol. 1984;6:259. doi: 10.1016/0192-0561(84)90041-9. [DOI] [PubMed] [Google Scholar]
  • 6.Cunningham, Szenberg A. Further improvements in the plaque technique for detecting single antibody forming cells. Immunology. 1968;14:599. [PMC free article] [PubMed] [Google Scholar]
  • 7.Hersh EM, Gutterman JU, Mavligit GN. Immunotherapy of human cancer. Adv Int Med. 1977;22:145. [PubMed] [Google Scholar]
  • 8.Hoffmann MK, Weiss O, Koenig S, Hirst JA, Oettgen HF. Suppression and enhancement of T cell dependent production of antibody to SRBC in vitro by bacterial lipopolysaccharide. J Immunol. 1975;114:738. [PubMed] [Google Scholar]
  • 9.Ibraheim HE, Nigam VN, Brailovsky CA, Backman BD, Elhilali MM. Combined cyclophosphamide chemotherapy and maltose tetrapalmitate immunotherapy in the treatment of transplanted prostate and bladder carcinoma of the rat. Cancer Res. 1984;44:546. [PubMed] [Google Scholar]
  • 10.Ibraheim HE, Kappany H, Nigam VN, Brailovsky CA, Madarnas P, Elhilali MM. Adjuvant immunotherapy of N-[4-(5[nitro-2-furyl)-2-thiazolyl] formamide-induced bladder tumors. Anticancer Res. 1984;4:209. [PubMed] [Google Scholar]
  • 11.Ibraheim HE, Kappany H, Elhilali MM, Nigam VN, Brailovsky CA. Prophylactic maltose tetrapalmitate and BCG immunotherapy for recurrent superficial bladder tumors. Proc Am Urol Assoc. 1985;80:211A. doi: 10.1016/s0022-5347(17)41701-0. [DOI] [PubMed] [Google Scholar]
  • 12.Jakway JP, Defranco AL. Pertussis toxin inhibition of B-cell and macrophage responses to bacterial lipopolysaccharide. Science. 1986;234:743. doi: 10.1126/science.3095921. [DOI] [PubMed] [Google Scholar]
  • 13.Kappany H, Chopra C, Nigam VN, Brailovsky CA, Elhilali MM. A comparison of the antitumor activity of maltose tetrapalmitate with other immunoadjuvants and its effectiveness after tumor surgery. Br J Cancer. 1980;42:703. doi: 10.1038/bjc.1980.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kato A, Ando K, Tamura G, Arima J. Effects of some fatty acid esters on the viability and transplantability of Ehrlich ascites tumor cells. Cancer Res. 1971;31:501. [PubMed] [Google Scholar]
  • 15.Kotani S, Takada H, Tsuijimoto M, Ogawa T, Harada K, Mori Y, Kawasaki A, Tanaka A, Nagao S, Tanaka S, Shiba T, Kusumoto S, Imoto M, Yoshimura H, Yamamoto M, Shimamoto T. Immunobiologically active lipid A analogs synthesized according to a revised structural model of natural lipid A. Infect Immun. 1984;45:293. doi: 10.1128/iai.45.1.293-296.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kotani S, Takada H, Tsuijimoto M, Ogawa T, Mori Y, Sakuta M, Kawasaki A, Inage M, Kusumoto S, Shiba T, Kasai N. Immunobiological activities of synthetic lipid A analogs and related compounds as compared to those of bacterial lipopolysaccharide, reglycolipid, lipid A and muramyl dipeptide. Infect Immun. 1984;41:758. doi: 10.1128/iai.41.2.758-773.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Munford RS, Hall CF. Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. Science. 1986;234:203. doi: 10.1126/science.3529396. [DOI] [PubMed] [Google Scholar]
  • 18.News Item. Sucrose polyester lowers cholesterol levels (1978) Chem Eng News Dec 4, p 26
  • 19.Nigam VN, Brailovsky CA, Chopra C. Maltose tetrapalmitate: a non-toxic immunopotentiator with antitumor activity. Cancer Res. 1978;38:3315. [PubMed] [Google Scholar]
  • 20.Nigam VN, Bonaventure J, Chopra C, Brailovsky CA. Effects of structural variation in synthetic glycolipids upon mitogenicity for spleen lymphocytes, adjuvancy for humoral immune response and on antitumor potential. Br J Cancer. 1982;46:782. doi: 10.1038/bjc.1982.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nigam VN, Brière N, Bonaventure J, Pageau R, Bissonnette E, Brailovsky CA, Madarnas P. Combined radiotherapy, chemotherapy and maltose tetrapalmitate immunotherapy in the treatment of 4′-dimethyl-aminoazobenzene-induced liver cancer. Anticancer Res. 1986;6:245. [PubMed] [Google Scholar]
  • 22.Nishikawa Y, Yoshimoto K, Nishijima M, Fukuoka F, Ikekawa T. Chemical and biochemical studies on carbohydrate esters IX. Antitumor effects of selectively fatty acylated products of maltose. Chem Pharm Bull. 1981;29:505. doi: 10.1248/cpb.29.505. [DOI] [PubMed] [Google Scholar]
  • 23.Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science. 1984;225:1365. doi: 10.1126/science.6147898. [DOI] [PubMed] [Google Scholar]
  • 24.Pageau R, Nigam VN, Fisher GJ, Brailovsky CA, Fathi MA, Corcos J, Tahan TW, Elhilali MM. Combination of 60Co Y-radiation, misonidazole and maltose tetrapalmitate in the treatment of Dunning prostatic tumor in the rat. Int J Rad Oncol Biol Phys. 1985;11:1483. doi: 10.1016/0360-3016(85)90336-0. [DOI] [PubMed] [Google Scholar]
  • 25.Rollinghoff MA, Starzinski-Powitz K, Pfizenmaier K, Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen specific cytotoxic T lymphocytes. J Exp Med. 1977;145:455. doi: 10.1084/jem.145.2.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rosenstreich DL, Asselineau J, Mergenhagen SE, Nowotny A. Synthetic glycolipid with B cell mitogenic activity. J Exp Med. 1974;140:1404. doi: 10.1084/jem.140.5.1404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tanamoto KI, Galanos C, Luderitz O, Shiba T. Mitogenic activities of synthetic lipid A analogs and suppression of mitogenicity of lipid A. Infect Immun. 1984;44:427. doi: 10.1128/iai.44.2.427-433.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Tanamoto KI, Zhringer U, McKenzie GR, Galanos C, Rietschel ETH, Luderitz O, Kusumoto S, Shiba T. Biological activities of synthetic lipid A. Analogs: pyrogenicity, lethal toxicity, anticomplement activity, and induction of gelation of limulus amoebocyte lysate. Infect Immun. 1984;44:421. doi: 10.1128/iai.44.2.421-426.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Watson J, Riblet R. Genetic control of responses to bacterial lipopolysaccharides in mice I. Evidence for a single gene that influences mitogenic and immunogenic responses to lipopolysaccharides. J Exp Med. 1974;140:1147. doi: 10.1084/jem.140.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Watson J, Riblet R, Taylor BA. The responses of recombinant inbred strains of mice to bacterial lipopolysaccharides. J Immunol. 1977;118:2088. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES